|
COPYRIGHT 2006 International Medical News Group
LOS ANGELES -- An attenuated herpes zoster virus vaccine effectively prevents herpes zoster and postherpetic neuralgia, according to a presentation by Dr. Samuel Cykert at the annual meeting of the Society of General Internal Medicine.
The vaccine (Zostavax, Merck & Co.), which was licensed for use in people age 60 years and older by the Food and Drug Administration in late May, is administered as a single injection. The lifetime risk of symptomatic shingles is estimated at 2 in every 10 people, the FDA noted in a statement announcing the licensure of...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
